[
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Short Interest in Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY) Grows By 100.0%",
        "description":"Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY \u2013 Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 200 shares, a growth of 100.0% from the August 31st total of 100 shares. Base\u2026",
        "content":"Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY \u2013 Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 200 shares, a gro\u2026 [+1584 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/28\/short-interest-in-hikma-pharmaceuticals-plc-otcmktshkmpy-grows-by-100-0\/",
        "source":"ETF Daily News",
        "published_at":1727555866000,
        "collected_at":1727696508188,
        "sentiment_label":"Neutral",
        "sentiment_probabolity":0.9999016523,
        "sentiment_vector":0.0
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Short Interest in Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Declines By 17.0%",
        "description":"Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF \u2013 Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 1,574,300 shares, a decrease of 17.0% from the July 31st total o\u2026",
        "content":"Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF \u2013 Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 1,57\u2026 [+1465 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/02\/short-interest-in-hikma-pharmaceuticals-plc-otcmktshkmpf-declines-by-17-0\/",
        "source":"ETF Daily News",
        "published_at":1725278337000,
        "collected_at":1727696508188,
        "sentiment_label":"Negative",
        "sentiment_probabolity":0.9194571972,
        "sentiment_vector":-0.9194571972
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Hikma Pharmaceuticals just upgraded at Berenberg, here's why",
        "description":"See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor\u2026",
        "content":"Earnings calls, analyst events, roadshows and more",
        "url":"https:\/\/thefly.com\/permalinks\/entry.php\/id3976931\/HKMPF-Hikma-Pharmaceuticals-just-upgraded-at-Berenberg-heres-why",
        "source":"Thefly.com",
        "published_at":1725351867000,
        "collected_at":1727696508188,
        "sentiment_label":"Neutral",
        "sentiment_probabolity":0.9998342991,
        "sentiment_vector":0.0
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Berenberg upgrades Hikma Pharmaceuticals on renewed growth confidence",
        "description":"Berenberg upgrades Hikma Pharmaceuticals on renewed growth confidence",
        "content":"On Tuesday, Hikma Pharmaceuticals (OTC:HKMPY) Plc (LSE:HIK) (OTC:HKMPF) stock received an upgrade in its rating from Hold to Buy, along with an increase in its price target from GBP21.00 to GBP24.00.\u2026 [+1663 chars]",
        "url":"https:\/\/www.investing.com\/news\/company-news\/berenberg-upgrades-hikma-pharmaceuticals-on-renewed-growth-confidence-93CH-3597335",
        "source":"Investing.com",
        "published_at":1725354344000,
        "collected_at":1727696508188,
        "sentiment_label":"Positive",
        "sentiment_probabolity":0.9999998808,
        "sentiment_vector":0.9999998808
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Berenberg Bank Upgrades Hikma Pharmaceuticals (LON:HIK) to Buy",
        "description":"Hikma Pharmaceuticals (LON:HIK \u2013 Get Free Report) was upgraded by research analysts at Berenberg Bank to a \u201cbuy\u201d rating in a report released on Monday, MarketBeat.com reports. The brokerage currently has a GBX 2,400 ($31.56) price target on the stock, up from\u2026",
        "content":"Hikma Pharmaceuticals (LON:HIK \u2013 Get Free Report) was upgraded by research analysts at Berenberg Bank to a \u201cbuy\u201d rating in a report released on Monday, MarketBeat.com reports. The brokerage currently\u2026 [+2192 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/04\/berenberg-bank-upgrades-hikma-pharmaceuticals-lonhik-to-buy\/",
        "source":"ETF Daily News",
        "published_at":1725429532000,
        "collected_at":1727696508188,
        "sentiment_label":"Positive",
        "sentiment_probabolity":0.9994063377,
        "sentiment_vector":0.9994063377
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"thyssenkrupp (OTCMKTS:TKAMY) versus Hikma Pharmaceuticals (OTCMKTS:HKMPF) Critical Survey",
        "description":"thyssenkrupp (OTCMKTS:TKAMY \u2013 Get Free Report) and Hikma Pharmaceuticals (OTCMKTS:HKMPF \u2013 Get Free Report) are both mid-cap basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their earning\u2026",
        "content":"thyssenkrupp (OTCMKTS:TKAMY \u2013 Get Free Report) and Hikma Pharmaceuticals (OTCMKTS:HKMPF \u2013 Get Free Report) are both mid-cap basic materials companies, but which is the superior business? We will comp\u2026 [+4910 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/09\/thyssenkrupp-otcmktstkamy-versus-hikma-pharmaceuticals-otcmktshkmpf-critical-survey\/",
        "source":"ETF Daily News",
        "published_at":1725880366000,
        "collected_at":1727696508188,
        "sentiment_label":"Positive",
        "sentiment_probabolity":0.9999997616,
        "sentiment_vector":0.9999997616
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Hikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts",
        "description":"Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have earned a consensus rating of \"Moderate Buy\" from the six research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with \u2026",
        "content":"Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have earned a consensus rating of \"Moderate Buy\" from the six research firms that are currently covering the company, MarketBeat report\u2026 [+138 chars]",
        "url":"https:\/\/biztoc.com\/x\/89b6ae2e363658c8",
        "source":"Biztoc.com",
        "published_at":1727333144000,
        "collected_at":1727696508188,
        "sentiment_label":"Positive",
        "sentiment_probabolity":0.6774064898,
        "sentiment_vector":0.6774064898
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Hikma Pharmaceuticals (LON:HIK) Shares Cross Above 200 Day Moving Average of $1,917.24",
        "description":"Shares of Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,917.24 ($25.33) and traded as high as GBX 1,955.82 ($25.84). Hikma Pharmaceutic\u2026",
        "content":"Shares of Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,917.24 ($25.33) and\u2026 [+2357 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/21\/hikma-pharmaceuticals-lonhik-shares-cross-above-200-day-moving-average-of-1917-24\/",
        "source":"ETF Daily News",
        "published_at":1726898826000,
        "collected_at":1727696508188,
        "sentiment_label":"Neutral",
        "sentiment_probabolity":0.9999958277,
        "sentiment_vector":0.0
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Hikma Pharmaceuticals PLC (LON:HIK) Receives Average Recommendation of \u201cModerate Buy\u201d from Analysts",
        "description":"Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) has been given an average rating of \u201cModerate Buy\u201d by the six brokerages that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and three have as\u2026",
        "content":"Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) has been given an average rating of \u201cModerate Buy\u201d by the six brokerages that are covering the stock, MarketBeat reports. Three investment analys\u2026 [+2469 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/01\/hikma-pharmaceuticals-plc-lonhik-receives-average-recommendation-of-moderate-buy-from-analysts\/",
        "source":"ETF Daily News",
        "published_at":1725167726000,
        "collected_at":1727696508188,
        "sentiment_label":"Neutral",
        "sentiment_probabolity":0.5403329134,
        "sentiment_vector":0.0
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Hikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Rating of \u201cModerate Buy\u201d from Brokerages",
        "description":"Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) has received an average rating of \u201cModerate Buy\u201d from the six research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation an\u2026",
        "content":"Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) has received an average rating of \u201cModerate Buy\u201d from the six research firms that are covering the firm, Marketbeat Ratings reports. Two research\u2026 [+2291 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/26\/hikma-pharmaceuticals-plc-lonhik-receives-consensus-rating-of-moderate-buy-from-brokerages\/",
        "source":"ETF Daily News",
        "published_at":1727332145000,
        "collected_at":1727696508188,
        "sentiment_label":"Positive",
        "sentiment_probabolity":0.983505547,
        "sentiment_vector":0.983505547
    },
    {
        "company":"Hikma Pharmaceuticals",
        "ticker":"HIK",
        "title":"Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200-Day Moving Average of $1,918.45",
        "description":"Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,918.45 ($25.09) and traded as high as GBX 1,928.18 ($25.21). Hikma Pharmaceuticals\u2026",
        "content":"Hikma Pharmaceuticals PLC (LON:HIK \u2013 Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,918.45 ($25.09) and tr\u2026 [+2401 chars]",
        "url":"https:\/\/www.etfdailynews.com\/2024\/09\/11\/hikma-pharmaceuticals-lonhik-stock-price-crosses-above-200-day-moving-average-of-1918-45\/",
        "source":"ETF Daily News",
        "published_at":1726043482000,
        "collected_at":1727696508188,
        "sentiment_label":"Neutral",
        "sentiment_probabolity":0.9999973774,
        "sentiment_vector":0.0
    }
]